Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial

Lignende værker

• Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
  af: Hopkins, Ashley M, et al.
  Udgivet: (2020)
• Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer
  af: Abuhelwa, Ahmad Y., et al.
  Udgivet: (2021)
• Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176
  af: Auclin, Edouard, et al.
  Udgivet: (2021)
• Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non–Small Cell Lung Cancer
  af: Kichenadasse, Ganessan, et al.
  Udgivet: (2019)
• The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data
  af: Modi, Natansh D., et al.
  Udgivet: (2021)